The minimum clinically important difference (MCID) for a falls intervention in Parkinson's:A delphi study by Henderson, Emily et al.
                          Henderson, E., Morgan, G., Amin, J., Gaunt, D., & Ben-Shlomo, Y. (2019).
The minimum clinically important difference (MCID) for a falls intervention





Link to published version (if available):
10.1016/j.parkreldis.2018.11.008
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Elsevier at https://www.sciencedirect.com/science/article/pii/S1353802018304899 . Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
  1 
Parkinsonism and related disorders 
The minimum clinically important difference (MCID) for a falls 
intervention in Parkinson’s: A delphi study 
Emily J Henderson1,2, Gemma S Morgan1, Jigisha Amin3, Daisy M Gaunt4, Yoav Ben-
Shlomo1 
 
1. Department of Population Health Sciences, Bristol Medical School, University of 
Bristol, 39 Whatley Road, Bristol. BS8 2PS. United Kingdom 
2. Royal United Hospitals NHS Foundation Trust Bath, BA1 3NG. United Kingdom 
3. Faculty of Health Sciences, Bristol Medical School, University of Bristol, Bristol. 
BS8 2PS. United Kingdom 
4. Bristol Randomised Trials Collaboration (BRTC), Department of Population Health 
Sciences, Bristol Medical School, University of Bristol, 39 Whatley Road, Bristol. 
BS8 2PS. United Kingdom 
 
Correspondence should be addressed to Emily J Henderson; Emily.henderson@bristol.ac.uk 
  
  2 
Abstract 
Background:  Falls are common in Parkinson’s disease so any intervention that reduced falls 
risk would be of value. One potential intervention is the use of cholinesterase inhibitor (ChEi) 
drugs. 
 
Objective: To establish the minimum clinically important difference (MCID) for fall rates to 
inform the effect estimate for sample size calculations of future clinical trials 
 
Methods: We performed a Delphi study assembling a panel of experts in Parkinson’s disease 
from academic and clinical medicine in order to reach a consensus of opinion. Responses 
from a panel were summarised and resent to the group, until consensus was reached.  
 
Results: 780 clinicians, who had been caring for people with Parkinson’s for an average of 
14 years, were contacted via three routes. The median (Interquartile range (IQR)) MCID after 
round 1 was 25% (IQR 20-30%) which equates to the prevention of 5 (IQR 4-6) falls per 
year. Increasing consensus after round two confirmed the MCID of 25%, narrowing the (IQ) 
range to 20%-25%.  This was unchanged when the panel were shown the number of 
participants that would need to be recruited to a clinical trial in order to achieve this 
difference. 
 
Conclusions: We have established that an expert panel of PD specialists consider that an 
intervention that demonstrated a 25% (IQR 20-25%) relative reduction in falls rate would be 
clinically meaningful. This estimate can be used to help determine the sample size for any 
future clinical trial.  
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Introduction 
Falls are a frequent and serious complication of Parkinson’s disease (PD).  Prospective 
studies report that 60% of people with PD have at least one fall per year and 39% fall 
recurrently [1]; median survival in patients with PD who have recurrent falls is 6 years [2]. 
Even in those who have not previously fallen, 21% will fall in the next 3 months. 
Consequences of falls include fractures and injury [3], fear of future falls [4], hospital 
admission [5], and increased caregiver burden [6], with falls cited as one of the worst aspects 
of the disease.  
 
There is an urgent and unmet need to identify strategies to reduce the risk of falls and the 
potentially devastating sequelae in this high-risk population.  Two strategies to tackle falls in 
PD are physical therapy [7–11] and the use of cholinesterase inhibitor (ChEi) drugs.  Three 
randomised controlled trials of ChEi have demonstrated statistically significant differences in 
falls  [12–14]. However, it is yet unknown as to whether these changes equate to a clinically 
important difference.  
 
A statistically important difference is mainly determined by the number of people measured 
[15] and may not equate to a clinically important difference, even with an effective 
intervention (see reference [15] for a review of methods to determine cut-points for 
continuous scales). Clinicians must therefore determine whether a reported statistically 
significant difference would translate to a meaningful clinical benefit.  This benefit, termed 
the clinically important difference, is a change that patients and/or clinicians would deem to 
be important to health or quality of life [16]. The lowest threshold value of this measure is the 
minimum clinical important difference (MCID), defined as “the smallest change or difference 
in an outcome measure that is perceived as beneficial and would lead to a change in the 
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patient’s medical management, assuming an absence of excessive side effects and costs” 
[17,18]. As this value is subjective, the estimate of this will vary between individuals 
rendering it necessary to reach a consensus opinion.   
 
We used a Delphi survey to determine the MCID for the number of falls that would need to 
be reduced in a hypothetical trial to be clinically meaningful. A Delphi survey consists of an 
iterative, multistep process in order to reach a consensus. Responses from a panel of experts 
are summarised and re-sent to the group recurrently until consensus is reached [19]. A key 
feature of this widely used methodology is the anonymity that is maintained between 
participants throughout the structured feedback process [20]. Currently there is no accepted 
MCID for reducing falls risk in patients with PD. The aim of this paper was to perform a 
Delphi survey of experts in the field of PD in order to establish the MCID for the potential 
intervention of ChEi therapy, which can then be used to design future clinical.  
Methods 
Participants 
We sought to identify experts in PD who practised in academic and / or clinical settings.  We 
defined an expert as a) a clinician with a specialist interest (defined as performing ≥1 
specialist Movement Disorder clinic/ week and attending ≥ 1 recognised Continuing 
Professional Development (CPD) activity (meeting /conference/course) in PD per year and / 
or b) an academic who holds a tenured or honorary university post who has published at least 
1 peer-reviewed journal article in the last three years in the field of falls and PD. Potential 
participants were approached via three routes:  Clinicians with an interest in Movement 
Disorders were contacted via two UK mailing lists (the British Geriatrics Society Movement 
Disorders Section (BGS-MDS) and the Association of British Neurologists (ABN)). A 
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systematic review of the literature was undertaken using the MESH headings ‘Falls’ and 
‘Parkinson disease’, limited to the last 2 years.  From this, the corresponding author was 
emailed.  If no email address was listed on the paper, their institution website was checked.  
Alternatively, the first or last author was contacted if no contact details were obtainable. All 
experts remained blinded to the identity of other experts.  Completion of the online survey 
was piloted by physicians who did not have an explicit interest in PD. 
Survey 
An online survey was emailed to the experts with a follow-up reminder to non-responders.  
An introductory email provided information about the study and included a link to the online 
questionnaire.  Panellists were asked to respond within 2 weeks of receipt of the email.  The 
survey obtained some descriptive data about the participants and provided them with the 
background information including a fall rate ascertained from a robust systematic literature 
review [1].  The range in values of fall rate may result from patient characteristics in study 
samples, with high rates reported in those with cognitive impairment [21,22], the methods 
used for fall ascertainment and the classification of single versus recurrent faller [1]. 
Furthermore, it is recognised that a small proportion of patients will fall extremely frequently 
[10,13].   
 
The Prevention of Falls Network Europe (ProFaNE) consensus statement advocates the 
collection of data on falls, fall-related injuries, physical activity, psychological consequences, 
and generic health-related quality of life (HRQoL) in fall injury prevention trials [23]. Falls 
were selected as the outcome measure in this study as they represent the index event that 
leads to the other potential sequelae such as fractures, hospitalisation and decline in health-
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related quality of life.  Fall reduction is a meaningful outcome at both a population and 
individual level.  
 
Having had a previous fall is a useful predictor of future falls when used alone [24] or in 
combination with other risk factors [25]. In the most comprehensive review to date [1] 
recurrent fallers were defined as having had more than one fall in a reported time period 
which was then adjusted to reflect a 12 month period. A wide range of recurrent fall rates 
were reported across the studies from 4.7 to 67.6 falls per year (mean 20.8). We therefore 
used this average to anchor the study in order to apply the proposed treatment effects to a 
population. Clinicians making a decision on preventive treatment for falls in an individual 
patient with PD would not necessarily know in advance whether their patient is likely to have 
an annual fall rate at the lower or higher end, therefore using the mean value as an anchor 
also replicates pragmatic clinical decision-making. 
 
Participants were asked “In people with PD who have fallen, the average rate of recurrent 
falls is 20.8 falls per year (range 4.7 to 67.6). Please assume that a) the patient has no 
contraindication to cholinesterease inhibitor treatment and b) that a phase III trial has shown 
that cholinesterase inhibitor treatment results in a statistically significant reduction in fall 
rate.  What is the MINIMUM treatment effect you would need to see before you would 
routinely consider using a cholinesterase inhibitor for people with PD who have previously 
fallen? To consider cholinesterase inhibitor therapy for falls prevention it would have to 
decrease fall rate by at least… (choose one only):” 
The following options were presented both as a relative and absolute reduction in risk 
covering the range of between 2-50% or 1 to 10 falls prevented per year. For example, 
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relative reduction of 25% = 5 falls prevented over 1 year = fall rate change from 20.8 to 15.6 
falls/year (see data in Supplementary data 1a for all the options.) 
 
Those that completed the first round were invited to participate in a second round.  At this 
point, respondents were shown a figure demonstrating the median and range of all the 
responses and a reminder of their round 1 response so that they could decide to stay with their 
first response or alter this in the light of the responses from other participants.  The second 
round contained an additional question that also listed the number of potential trial 
participants that would be required for each effect size alongside the MCID question (see 
data in Supplementary data 1b). This was done to see if participants altered their opinion 
given the pragmatic issues around recruiting PD patients into RCTs. This question was 
presented at the end of the survey so it could not influence participants’ responses to the 
MCID question. A priori, we anticipated that 2 to 3 rounds would be necessary to achieve 
consensus. A copy of the MCID question is shown in Supplementary data 1. The survey was 
hosted on REDCap software.  Ethical approval was granted from the University of Bristol 
ethics committee on 4th July 2016.  
 
All analysis was carried using the Stata software version 15.1 (Stata Corporation, College 
Station, TX, USA). We reported results using descriptive statistics such as number of 
responses (percentages), means (SD) or median and (25% to 75% IQR), as appropriate. The 
MCID was summarised using the median due to the skewness of the data, which was 
assessed visually. We used the emails of responders to determine who had not responded and 
hence required a reminder. Missing data were possible but we did not use any imputation 
methods as the number of missing data items was small.  
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Results  
A total of 780 clinicians were contacted via the three routes (n=57 paper authors; n=408 BGS 
MDS mailing list; n= 315 ABN mailing list), a CONSORT flow diagram of recruitment is 
shown in Figure 1. One hundred and fifteen people responded to the round 1 invitation, of 
these; 13 did not want to take part. Of the 102 who were interested in participating, 35 did not 
give consent (so did not proceed to answer the remaining questions), 2 did not provide an 
email address for the follow-up survey to be sent and 2 did not respond to the MCID 
question, therefore 63 participant’s responses were analysed (8%).  54 participants responded 
to round 2 (86% of round 1).  
 
The demographics of the respondents are shown in Table 1.  The majority were based in 
Europe and had been caring for people with PD for an average of 14 years. The majority 
were frequent prescribers of ChEi.  The two most commonly cited limitations to ChEi use 
were concerns regarding side effects and efficacy.  
 
The median (interquartile range (IQR)) MCID after round 1 was 25% (IQR 20-30%) (Figure 
2) which equates to the prevention of 5 (IQR 4-6) falls per year. However, there was, as 
expected, a wide range with some participants regarding even 1 fall (2% relative reduction) 
prevented as being meaningful and others requiring a much larger 10 fall (50% relative 
reduction).  
 
The results of round 2 did not alter the MCID but narrowed the IQR - 25% (IQR 20%-25%) 
(Figure 3) which equates to a reduction of 5 falls (IQR4-5) per year. The median point 
estimate for MCID therefore remained unchanged but the range narrowed between the two 
rounds, suggesting greater consensus.  The consensus MCID remained unchanged (IQR 20-
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30%) when respondents were shown the total number of participants that would need to be 
recruited to a clinical trial in order to achieve that effect size (Supplementary data 2). 
 
As so few responders were based outside Europe it was not possible to determine whether 
estimates differed regionally. There was no difference between the median MCID estimated 
by clinicians versus academics nor geriatricians versus neurologists and no difference for 
those who had practised for 12 or more years compared with those who have less than 12 
years’ experience. Side effects and efficacy were the two most commonly cited reasons for 
non-prescription of ChEis. 
Discussion 
This study determined the MCID for a falls intervention trial, (e.g. a ChEi) to be 25% (IQR 
20%-25%) which equated to a reduction of 5 falls (IQR 4-5) per year in our hypothetical 
population.  This would equate to a moderate to large size trial (total sample size required: 
734, 367 per group in a 2-group study) given 90% power and 5% two-sided alpha.  Having 
ascertained the MCID, it will be possible to determine in future studies whether the reported 
point estimate is clinically important, i.e. if the MCID is smaller than the lower limit of the 
confidence interval [26]. This reduction is smaller than the 45-69% reduction in falls reported 
in the 3 randomised controlled clinical trials of ChEi treatment that have been performed to 
date [12–14].  
 
This is the first study known to the authors that has sought to determine the MCID for 
reduction falls in PD.  The study has several advantages.  We sought opinions from 
established specialists in PD and included clinicians and academics. Using an online tool 
meant that opinions were expressed anonymously in contrast to a group setting where 
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individuals can exert undue influence over a group [27].  In our study, we achieved adequate 
consensus with two rounds of the survey with a relatively high retention of participants.  
 
There are several limitations. The majority of experts were approached via UK based mailing 
lists and therefore the sample included high numbers of clinicians and academics from 
Europe. Though a Europe-focus was not exclusive, our sample may not therefore be wholly 
representative of worldwide PD specialists.  The proportion of experts who responded was 
low and therefore may have been biased although there was fair representation from 
academic and clinical specialists, the majority of whom had responsibility for patient care 
and prescribed ChEi.  Our panel size was larger than that utilised in other Delphi studies that 
have sought to determine clinically meaningful differences [28,29]. Repeating the exercise 
with a different panel sample would further inform the extent to which this opinion is 
generalisable to other experts in the field.  
 
It is anticipated that the MCID that we have determined pertains to the group differences 
ascertained in a randomised controlled trial.  Our anchor (the mean recurrent fall rate of 20.8 
falls per year) was therefore determined at an overall group level for a population of people 
with PD (see [30] for a comprehensive worked example). Our choice of the mean fall rate 
was based on a comprehensive systematic review of recurrent fallers [1]. It could be argued 
that the average fall rate could have more optimally been derived from the median fall rates 
from individual papers. An additional limitation is that the consensus has been derived using 
a scenario that applies to a hypothetical patient falling recurrently 21 times in 12 months and 
the wider generalizability to those falling more or less frequently is limited.   
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To apply the MCID at an individual level, group minimal difference can be used in trials as a 
response criterion to determine the proportion of patients in each arm whose change is greater 
than the MCID [31]. At an individual level for a person with PD who is falling, a 25% 
(relative reduction in fall rate will translate differently depending on the individual’s absolute 
risk.  This reduction will yield a greater absolute reduction in number of falls in the very 
frequent faller versus the occasional faller. At this individual level a more appropriate 
question to pose may be ‘what reduction in fall rate results in a minimally important 
improvement in quality of life’. For example, falls that result in significant soft tissue 
injuries, fractures and hospitalisation may negatively impact patients to a greater extent that 
simply the number of falls.  Therefore, these alternative outcome measures may be of more 
importance to patients than the reduction in overall fall rate. To determine meaningful 
differences at the individual level, it is therefore important to capture changes in fall 
sequelae, including patient quality of life.   
 
In our study, we did not seek to subclassify the aetiology of the fall or the characteristics of 
the faller.   Future trials and meta-analyses should be able to identify whether a given fall 
intervention performs differently depending on pre-existing fall risk and other factors such as 
age or gender.  Interventions that are effective in those at higher risk of falling have the 
potential to be more cost-effective. This process is aided by the standardisation of the fall 
trials outcomes in line with the ProFaNE consensus [23].  We recognise that a smaller 
difference in improvement in fall rate may be accepted if it led to a clinically meaningful 
difference in disability related measures and quantifying meaningful differences across fall 
related domains offers a promising avenue for future study.    
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We chose to contextualise our scenario with a potential drug intervention (ChEi). We think 
our findings are likely generalisable to other drugs treatments. Assuming no major 
differences in serious side effects, the cost-effectiveness of two equally effective treatments 
will be sensitive to the cost of the therapies. Our findings may not be generalisable to clinical 
decisions about patients whose fall rates differ markedly from the mean value used in this 
study. It is less clear if our findings are generalizable to non-pharmacological interventions 
such as physiotherapy. In principle, there should be no difference but we cannot be sure that 
clinicians do not hold different expectations from such interventions.  Commonly, non-
pharmacological interventions are considered to have fewer negative effects therefore 
clinicians may have a lower threshold for the MCID required for them to consider a non-
pharmacological prescription.”   
 
This study ascertained the MCID for a falls intervention using a Delphi process to obtain 
consensus amongst experts. This difference translates to a meaningful clinical benefit, 
derived from experienced academics and practising clinicians, which researchers should take 
into account when designing trials of fall interventions in PD. There are future opportunities 
to perform research to ascertain consensus opinion in patients and caregivers on other 
outcomes, such as quality of life or reduced caregiver burden, that a falls intervention should 
be expected to deliver.  
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